BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:YKST02 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of YKST02\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06574568-3274@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:YKST02: Phase 1 readout est. (NCT06574568)
DESCRIPTION:YKST02\, phase 1\, Multiple Myeloma.\nStudy: A Study of YKST02 
 in Participants With Relapsed or Refractory Multiple Myeloma\nEstimated pr
 imary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ykst02#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06574568
URL:https://assetmemo.bio/drug/ykst02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498673-3274@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:YKST02: Phase 1 readout est. (NCT07498673)
DESCRIPTION:YKST02\, phase 1.\nStudy: A Study of YKST02 in Participants Wit
 h Primary IgA Nephropathy\nEstimated primary completion: 30 March 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ykst02#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07498673
URL:https://assetmemo.bio/drug/ykst02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512947-3274@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:YKST02: Phase 1 readout est. (NCT07512947)
DESCRIPTION:YKST02\, phase 1.\nStudy: Study of YKST02 Alone or in Combinati
 on With YK012 in Patients With Active or Refractory Systemic Lupus Erythem
 atosus\nEstimated primary completion: 30 March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ykst02#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07512947
URL:https://assetmemo.bio/drug/ykst02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695740-3274@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:YKST02: Phase 2 readout est. (NCT07695740)
DESCRIPTION:YKST02\, phase 2\, Multiple Myeloma.\nStudy: Study of YKST02 in
  Adults With Relapsed or Refractory Multiple Myeloma\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ykst02#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07695740
URL:https://assetmemo.bio/drug/ykst02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
